FDA-Approved Drug Could Help Prevent Liver Cancer

Select Language:

Credit: Unsplash+

Globally, fatty liver disease is becoming more widespread, particularly as obesity, diabetes, and metabolic syndrome rates climb.

Many people underestimate fatty liver as a minor concern, but it can cause severe health issues over time. Notably, it may lead to liver cancer, a major cause of cancer deaths worldwide.

A recent study from the University of Hong Kong offers promising insights. Researchers found that an existing drug used for fatty liver treatment could also slow down and prevent liver cancer development.

The study was conducted by scientists from the LKS Faculty of Medicine and the HKU State Key Laboratory of Liver Research. Their findings were published in *Hepatology*.

Liver cancer, or hepatocellular carcinoma, ranks as the sixth most common cancer globally and the third leading cause of cancer-related fatalities.

In recent years, there’s been a shift with more liver cancer cases linked to metabolic issues rather than infections or alcohol consumption. This form of cancer often associates with metabolic dysfunction-related fatty liver disease, known as MAFLD.

Estimates indicate that about 3% of individuals with fatty liver may develop liver cancer each year, with especially high rates in Asia, where many suffer from fatty liver disease.

While treatments like immunotherapy exist for advanced liver cancer, they are not always effective for cases linked to fatty liver. This has prompted scientists to seek new strategies for understanding and tackling the disease.

Using a mouse model closely mimicking human fatty liver, researchers examined how liver and immune cells change as cancer develops. They employed advanced methods to analyze cellular interactions during disease progression.

One significant discovery involved a protein called Midkine, or MDK. They found that MDK and its receptor activate a pathway that fosters tumor growth. Elevated MDK levels alter immune cell behavior, turning immune defenses into supporters of cancer growth.

For instance, macrophages, which typically clear harmful substances, begin to facilitate tumor development. Meanwhile, T cells, normally tasked with attacking cancer cells, lose their effectiveness, creating an environment conducive to tumor expansion and immune evasion.

Higher MDK levels also correlate with poorer outcomes in patients with fatty liver-related liver cancer. Those with increased MDK tend to face higher recurrence rates and shorter disease-free periods after treatment.

The study also focused on Resmetirom, a drug already approved by the FDA for fatty liver disease. Remarkably, Resmetirom not only decreases liver fat and improves metabolism but also reduces MDK levels and hampers tumor growth.

In experiments, Resmetirom displayed strong anti-cancer effects, and combined with MDK inhibitors, the impact was even greater. This combo improved liver function, decreased fat accumulation, and suppressed tumor growth more effectively than single treatments. It also fostered a healthier immune environment in the liver, less supportive of cancer.

These findings imply Resmetirom could serve to prevent liver cancer in high-risk individuals, in addition to treating fatty liver disease. This preventative approach could represent a major leap forward—addressing root causes early rather than waiting for cancer to manifest.

However, more research is necessary before translating these findings into clinical practice. Larger clinical trials are needed to confirm effects and determine optimal combinations with other therapies like immunotherapy.

Overall, this research sheds new light on how fatty liver disease progresses to cancer and introduces a promising preventive and therapeutic strategy. Targeting both metabolic dysfunction and cancer pathways, Resmetirom may pave the way for more comprehensive liver health management.

While the early-stage animal studies are promising, including the identification of the MDK pathway’s role in immune suppression, human trials are crucial. Confirming similar results in people could soon reshape how fatty liver disease and related cancer risks are handled, emphasizing early intervention and metabolic health.

If you’re interested in liver health, explore simple habits that promote liver wellness or common diabetes medications that might reverse liver inflammation.

For additional insights, review recent research on simple blood tests that indicate fatty liver risk or diet strategies like green eating that could significantly lower non-alcoholic fatty liver disease.